Results 1 to 10 of about 134,446 (292)
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Biomarker ResearchCell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity.
Dominik Sonanini +17 more
doaj +4 more sources
INPP5K limits PtdIns (4,5)P2 accumulation in CD19 microclusters and restrains CD19 co-receptor membrane proximity and BCR-proximal signaling in B cells [PDF]
Frontiers in ImmunologyIntroductionCD19 is a key B-cell co-receptor that amplifies B-cell receptor (BCR) signaling and tunes B-cell activation thresholds. How the conformation of the CD19 cytoplasmic domain is regulated to restrain basal and BCR-induced signaling remains ...
Bastien Moës +7 more
doaj +2 more sources
CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab [PDF]
Frontiers in ImmunologyIntroductionThe potential risk of eliminating or reducing CD19 expression following CD19-targeted therapies has raised questions about the optimal treatment sequencing strategies for B-cell malignancies. This study assessed CD19 expression and mutational
Johannes Duell +10 more
doaj +2 more sources
A study on influence of different signal peptides on anti-tumor effect of chimeric antigen receptor (CAR) T cells [PDF]
Zhongguo aizheng zazhi, 2022 Background and purpose: Signal peptide (SP) is a short peptide chain at the N-terminal of precursor protein, which can regulate the folding and transfer of precursor protein and plays an important role in protein secretion.
LI Fan, ZHANG Qinxing, TONG Xiangwen, TIAN Gaohui, GU Lixing, XU Yao
doaj +3 more sources
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19
Hematology/Oncology and Stem Cell Therapy, 2022 Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells.
Yenny M. Vanegas +6 more
doaj +1 more source
Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo
Frontiers in Bioscience-Landmark, 2020 Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated clinical success in treatment of B-cell hematologic cancers. In this study, we compared human Transferrin epitope tagged CAR-T cells with non-tagged CAR-T cells for cytotoxicity, IFN ...
Michael Valentine +9 more
doaj +1 more source
Pharmaceutics, 2020 Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia
Gils Roex +8 more
doaj +1 more source
Immunological Medicine, 2021 Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj +1 more source
The Cancer Journal, 2014 CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs).
Carlos A, Ramos +2 more
openaire +2 more sources
Hematology/Oncology and Stem Cell Therapy, 2022 Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3Z activatory domain connected to 4-1BB costimulatory domain.
Mohamed A. Kharfan-Dabaja +4 more
doaj +1 more source